Xspray Pharma AB (XSPRAY) Stock Statistics & Valuation Metrics

Xspray Pharma AB has a market cap or net worth of kr1.14B. The enterprise value is kr1.36B.

Xspray Pharma AB has 30,872,599 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xspray Pharma AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Xspray Pharma AB is -5.62. Xspray Pharma AB’s PEG ratio is -0.55.

In the last 12 months, Xspray Pharma AB had revenue of 0.00 and earned -179.67M in profits. Earnings per share was -6.76.

In the last 12 months, operating cash flow was -222.37M and capital expenditures -42.14M, giving a free cash flow of -264.51M billion.

Xspray Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xspray Pharma AB upcoming earnings date is May 7, 2025, TBA Not Confirmed.

Xspray Pharma AB as a current ratio of 5.46, with Debt / Equity ratio of 20.58%

In the past 12 months, Xspray Pharma AB has paid -17.00K in taxes.

Xspray Pharma AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Xspray Pharma AB has kr208.24M in cash and marketable securities with kr8.28M in debt, giving a net cash position of -kr80.02M billion.

Gross margin is -153.85%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Xspray Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―